vs
Side-by-side financial comparison of INDEPENDENCE REALTY TRUST, INC. (IRT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $165.3M, roughly 1.2× INDEPENDENCE REALTY TRUST, INC.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 2.5%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 2.2%).
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IRT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $165.3M | $196.9M |
| Net Profit | — | — |
| Gross Margin | — | 79.5% |
| Operating Margin | — | 1.2% |
| Net Margin | — | — |
| Revenue YoY | 2.5% | 5.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $165.3M | — | ||
| Q4 25 | $167.1M | $196.9M | ||
| Q3 25 | $167.1M | $179.5M | ||
| Q2 25 | $162.2M | $181.1M | ||
| Q1 25 | $161.2M | $168.9M | ||
| Q4 24 | $161.0M | $187.3M | ||
| Q3 24 | $160.1M | $168.6M | ||
| Q2 24 | $158.4M | $178.0M |
| Q1 26 | — | — | ||
| Q4 25 | $33.3M | — | ||
| Q3 25 | $6.9M | $5.4M | ||
| Q2 25 | $8.0M | $-4.8M | ||
| Q1 25 | $8.4M | $4.8M | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $12.4M | $-143.5M | ||
| Q2 24 | $10.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | — | ||
| Q3 25 | 4.1% | 3.0% | ||
| Q2 25 | 5.0% | -2.7% | ||
| Q1 25 | 5.2% | 2.8% | ||
| Q4 24 | -0.6% | — | ||
| Q3 24 | 7.7% | -85.1% | ||
| Q2 24 | 6.5% | 10.6% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.14 | $0.05 | ||
| Q3 25 | $0.03 | $0.12 | ||
| Q2 25 | $0.03 | $-0.11 | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $-0.01 | $0.38 | ||
| Q3 24 | $0.05 | $-3.11 | ||
| Q2 24 | $0.05 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.3M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $3.4B | $693.1M |
| Total Assets | $6.1B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $23.3M | — | ||
| Q4 25 | $23.6M | $238.4M | ||
| Q3 25 | $23.3M | $246.3M | ||
| Q2 25 | $19.5M | $445.9M | ||
| Q1 25 | $29.1M | $493.6M | ||
| Q4 24 | $21.2M | $484.6M | ||
| Q3 24 | $17.6M | $453.8M | ||
| Q2 24 | $21.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $372.2M | ||
| Q3 25 | $2.3B | $376.7M | ||
| Q2 25 | $2.2B | $580.5M | ||
| Q1 25 | $2.3B | $583.4M | ||
| Q4 24 | $2.3B | $585.3M | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.5B | $693.1M | ||
| Q3 25 | $3.5B | $727.2M | ||
| Q2 25 | $3.4B | $757.8M | ||
| Q1 25 | $3.5B | $798.5M | ||
| Q4 24 | $3.4B | $778.3M | ||
| Q3 24 | $3.4B | $749.6M | ||
| Q2 24 | $3.4B | $879.3M |
| Q1 26 | $6.1B | — | ||
| Q4 25 | $6.0B | $1.3B | ||
| Q3 25 | $6.1B | $1.3B | ||
| Q2 25 | $6.0B | $1.5B | ||
| Q1 25 | $6.0B | $1.6B | ||
| Q4 24 | $6.1B | $1.6B | ||
| Q3 24 | $5.9B | $1.5B | ||
| Q2 24 | $5.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.66× | 0.54× | ||
| Q3 25 | 0.66× | 0.52× | ||
| Q2 25 | 0.66× | 0.77× | ||
| Q1 25 | 0.65× | 0.73× | ||
| Q4 24 | 0.68× | 0.75× | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.66× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.1M | $43.7M | ||
| Q3 25 | $79.3M | $60.8M | ||
| Q2 25 | $82.2M | $12.0M | ||
| Q1 25 | $60.4M | $35.5M | ||
| Q4 24 | $259.8M | $33.1M | ||
| Q3 24 | $69.2M | $53.9M | ||
| Q2 24 | $83.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 8.48× | — | ||
| Q3 25 | 11.51× | 11.20× | ||
| Q2 25 | 10.22× | — | ||
| Q1 25 | 7.23× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.60× | — | ||
| Q2 24 | 8.02× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRT
| Rental and other property revenue | $165.2M | 100% |
| Other revenue | $109.0K | 0% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
